Welcome to our dedicated page for 3-D Sys Del news (Ticker: DDD), a resource for investors and traders seeking the latest updates and insights on 3-D Sys Del stock.
3D Systems Corporation (NYSE: DDD), a pioneer in additive manufacturing and digital dentistry solutions, provides investors and industry professionals with critical updates through this centralized news hub. Track official press releases, financial disclosures, and strategic developments from the company redefining 3D printing applications across healthcare, aerospace, and industrial manufacturing.
This resource offers timely access to earnings announcements, regulatory filings, and innovation milestones. Users will find updates on advanced manufacturing technologies like the Oqton Manufacturing OS, healthcare breakthroughs in patient-specific medical devices, and industrial applications of QuickCast Air investment casting solutions.
Key content categories include quarterly financial results, product launches, strategic partnerships, and regulatory compliance achievements. The curated collection serves as a reliable reference for assessing 3D Systems' market position and technological leadership in high-precision manufacturing.
Bookmark this page to stay informed about DDD's progress in materials science advancements, software platform enhancements, and global manufacturing initiatives. Check regularly for verified updates directly impacting investment decisions and industry analysis.
3D Systems (NYSE:DDD) has achieved a significant milestone in regenerative medicine as its bioprinting technologies enabled FDA De Novo marketing authorization for a first-of-its-kind peripheral nerve repair solution. The company collaborated with French MedTech firm TISSIUM to develop COAPTIUM® CONNECT with TISSIUM Light, a bioabsorbable 3D-printed medical device utilizing unique photopolymer technology.
This breakthrough combines TISSIUM's biomorphic programmable polymers with 3D Systems' bioprinting expertise to create high-resolution, elastomeric biodegradable implants. The development builds on 3D Systems' nearly decade-long leadership in bioprinting, including its collaboration with United Therapeutics Corporation for human lung development. The global bioprinting market is projected to grow from $1.3 billion in 2024 to $2.4 billion by 2029.
3D Systems (NYSE:DDD) has announced significant balance sheet improvements through strategic financial transactions. The company has successfully retired $88 million of debt (41% of prior balance) at a discount to par value and refinanced with $92 million in new Convertible Senior Secured Notes due 2030. Additionally, DDD has repurchased 8 million shares (approximately 6% of outstanding common stock) to reduce dilution.
Following these transactions, DDD's balance sheet will include $35 million in existing notes due 2026, $92 million in new notes due 2030, and approximately $140 million in cash reserves. The new notes will bear interest at 5.875% per annum and are convertible at a 20% premium to the June 17, 2025 closing price.
3D Systems (NYSE: DDD) is advancing digital dentistry with its NextDent® material portfolio, which addresses over 30 dental applications. The company's solutions focus on patient-specific devices for straightening, protecting, repairing, and replacing teeth. Their NextDent materials, compatible with NextDent 5100 and LCD1 printers, as well as other leading dental 3D printers, have received regulatory approvals across the US, Europe, and Asia.
The company's dental 'repair' market is projected to reach $150 million by 2029 in the US alone, representing one-third of the global market. Combined with other dental segments, the total US market opportunity is estimated at nearly $1 billion. Key materials include NextDent C&B MFH for crowns and bridges, and CROWNTEC™ through a partnership with Saremco Dental AG. 3D Systems' digital dentistry solutions have already served more than one million patients.
3D Systems (NYSE:DDD) has scheduled the release of its first quarter 2025 financial results after U.S. market hours on Monday, May 12, 2025.
The company will host a conference call and simultaneous webcast to discuss these results on Tuesday, May 13, 2025, at 8:30 a.m. Eastern Time. Investors and interested parties can participate through two channels:
- Webcast: Available at www.3dsystems.com/investor
- Telephone: Dial-in number 201-689-8345
A replay of the webcast will be made available approximately two hours after the conference call concludes, accessible through the company's investor relations website.
3D Systems (NYSE: DDD) has achieved a significant milestone in medical technology by enabling the world's first Medical Device Regulation (MDR)-compliant 3D-printed PEEK facial implant at the point-of-care. The breakthrough was accomplished in collaboration with the University Hospital Basel, Switzerland, where surgeons successfully implanted the device on March 18, 2025.
The implant was produced using VESTAKEEP® i4 3DF PEEK on 3D Systems' EXT 220 MED printer, which features cleanroom-based architecture and simplified post-processing workflows. Since its launch in August 2023, the EXT 220 MED has been used in over 80 successful cranial implant surgeries at partner hospitals.
The 3D-printed maxillofacial implant market is projected to grow from over $2 billion in 2024 to more than $4 billion by 2034. 3D Systems has already worked with surgeons to plan more than 150,000 patient-specific cases and manufacture over two million implants and instruments for 100+ CE-marked and FDA-cleared devices.
3D Systems (NYSE: DDD) unveils groundbreaking manufacturing solutions at RAPID+TCT 2025, introducing three key innovations:
- The Figure 4 135 3D printer with Figure 4 Tough 75C FR Black material, designed for high-mix, low-volume manufacturing, reducing costs significantly for precision applications
- A new module for EXT Titan Pellet printers that improves process efficiency up to 60% through enhanced part solidity optimization and print bed mapping
- The QuickCast Diamond build style for PSLA 270 technology, advancing investment casting pattern production
The Figure 4 135 solution targets industries requiring high precision with a process capability index of 1.33 or above. The new EXT Titan Pellet module, available in Q3 2025, reduces post-processing time by up to 50%. These innovations reflect 3D Systems' continued R&D investment and commitment to application-specific manufacturing solutions.
3D Systems (NYSE:DDD) has completed the sale of its Geomagic® software portfolio to Hexagon's Manufacturing Intelligence Division for $123 million, expecting net proceeds of approximately $100 million. The transaction strengthens the company's balance sheet and allows focus on core additive manufacturing software platforms.
The company will concentrate on advancing its key software solutions: 3D Sprint®, 3DXpert®, and Oqton Industrial Manufacturing OS. 3D Systems plans to enhance these platforms by leveraging artificial intelligence and automation to accelerate 3D printing adoption in high-volume production environments.